Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06221800 · ClinicalTrials.gov registry record
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
A clinical trial of Non-Small Cell Lung Cancer, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- 82
- Enrollment target
- 1
- Study location
NCT06221800 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 82 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06221800, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Microbiome
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06221800
The ClinicalTrials.gov registry entry for NCT06221800 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Microbiome is the first listed.
NCT06221800 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06221800 about?
NCT06221800 is a clinical study titled "Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects". This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
What is the current status of trial NCT06221800?
This trial is currently recruiting. The enrollment target is 82 participants. The study started on 2024-01-31. Estimated completion is 2026-12.
What conditions does trial NCT06221800 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06221800?
The interventions under investigation include: Microbiome (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06221800?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06221800 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.